One of the latest public health controversies has centered around the introduction and the rising popularity of electronic nicotine delivery systems. These devices most commonly called e-cigarettes or vaporizers, aerosolize various combinations of glycerol, propylene glycol, flavorings, nicotine, or cannabis to be inhaled by consumers. The marketing strategy for e-cigarettes is as a “healthier” alternative to traditional tobacco and a novel aid for smoking cessation with little data to support these claims. For chronic tobacco users, these new devices may lead to harm reduction by reducing exposure to many of the harmful effects of tobacco smoke. On the other hand, novel nicotine users will experience increased harm from the known hazards of nicotine consumption and may also suffer from unknown adverse health effects of other additives found in e-cigarettes. The biggest concern lies with use among adolescents and young adults. Early research suggests that e-cigarette use poses a higher risk for subsequent tobacco use later in youth and adulthood. Other studies show increased rates of respiratory symptoms, i.e., chronic cough, wheezing, and bronchitis with long-term use. Nicotine alone correlates with negative cardiovascular outcomes, including hypertension, coronary artery disease, and heart failure. The majority of e-cigarette companies are subsidiaries of large tobacco companies, and perhaps the most nefarious concern lies with the ongoing efforts of tobacco corporations to rebrand themselves to target the developing “cash-cow” that is the vulnerable adolescent population. Given the potential for benefit in specific populations and harm in others, more research is needed to delineate the accurate benefits of e-cigarettes as a smoking cessation aid versus the potential harm associated with long-term use.
Electronic nicotine delivery systems come in an array of designs. The primary differences are in nicotine concentration, the variety of additives and flavorings, battery type, and superficial aesthetics. The classic e-cigarette consists of a compact lithium-ion battery, a vaporization chamber, and a solvent mixture cartridge. The liquid is heated in the chamber and subsequently evaporated followed by rapid cooling. The aerosol is then directly inhaled orally by the user via a mouthpiece and leads to direct systemic absorption through the respiratory system. There have been several generations of e-cigarettes models. The earlier designs closely resemble the classic cigarette and deliver lower levels of nicotine. The latest models contain larger cartridges, higher-powered batteries, and lower resistance coils, which enhance the concentration of nicotine consumed. Cartridges can be exchanged easily between or during usage.
Particularly popular among youth consumers are the “pod-mod” class of devices that resemble a slick and modern universal serial bus drive. These super-compact vaporizers can deliver highly concentrated puffs at levels that would be aversive to even chronic tobacco users. Popular companies use nicotine formulations in their pod-mod devices that derive from the nicotine salts of loose-leaf tobacco. One pod of JUUL possesses the same amount of nicotine as twenty classic combustible cigarettes. Nicotine salts, when combined with additives and flavorings, mask the noxious taste of the ultra-concentrated nicotine. JUUL pods are about 9.4 by 1.5 by 0.8 centimeters and weigh approximately 0.01 kilograms. The modern, ultra-compact, and customizable designs are slick pieces of technology and allow discreet transport of the pods. This concealability has become a hot area of contention in schools who struggle to prevent students from vaping in restrooms, hallways, and classrooms. Furthermore, commercial marketing targets children with colorful exteriors and sweet flavors such as bubble gum, Doritos, and hello kitty to seductively increase their grip on this vulnerable demographic.
There are many constituents in the aerosols and liquids of e-cigarette cartridges. The most common include glycerol, propylene glycol, and nicotine. Micro-constituents that have been found in smaller concentrations include acrolein, formaldehyde, acetone, acetaldehyde, heavy metals, and many more. Most of the ingredients in individual flavorings have not undergone testing for long-term safety. One study in animals showed that inhalation of aerosolized glycerol and propylene glycol was associated with local squamous metaplasia in the upper airways. Known carcinogens like the various aldehyde compounds have been found in lower, but still, present concentrations when compared to traditional cigarettes. Heavy metals like chromium, nickel, and lead have also appeared in small quantities within the combustible vapor. These metals have known carcinogenic effects and are also associated with inflammation and damage. Varying manufacturing practices have shown discrepancies between levels of these compounds. Most research regarding exposure to e-cigarette aerosols has been completed either in vitro with cell cultures or in vivo with rodents. One study in mice looked at exposure to inhaled nicotine liquids and was associated with significant inflammation and oxidative stress to the pulmonary endothelium. Other mouse studies have shown a reduction in endothelial glutathione levels and increased inflammatory cytokines. Additionally, mice exposed to inhaled nicotine liquids showed higher rates of respiratory infections, including viruses and common bacteria.
Due to the profound cardiovascular and respiratory harm induced by conventional cigarettes, it is crucial for further research to help reveal the short-term and long-term consequences of the new alternatives. Early studies suggest a short-term increase in vital signs such as blood pressure and heart rate. Other studies have shown that e-cigarette vapors induce platelet activation in the endothelium of healthy naïve participants. Down the line, this could have implications for the risk of thrombosis. The risk of long term e-cigarette use has had direct research on humans. However, the negative effect of nicotine alone such as that found in e-cigarettes has been shown to have short-term side effects including gastrointestinal distress, palpitations, and headache. If absorbed in a large enough dose, nicotine can cause seizures, respiratory depression, and severe bradycardia. Doses tolerable to adults can be life-threatening if consumed by small children. It is easy to see how a sweet cartridge of flavor may be tempting to a young child and present as a toxic hazard.
Furthermore, exposure to any form of nicotine has been shown to impair the development of neural circuits and to lead to a permanent impairment of neurochemical and behavioral functioning. Teens and young adults are of particular concern for neurologic harm from the nicotine in e-cigarettes because the human brain does not cease development until the mid-twenties. Some epidemiologic studies suggest that women who consume nicotine during pregnancy risk neurotoxic effects on the developing fetus. The cholinergic system of the central nervous system is spread throughout the body and is vital for cognitive processes such as memory, attention, and executive processing. Nicotine itself can cross the placenta and bind to fetal nicotinic acetylcholine receptors. Evidence also exists that exposure to prenatal tobacco may harm fetal lung maturity, reduce lung compliance, impair overall lung function in infants, and possibly increase the risk of sudden infant death syndrome. Many women who were chronic cigarette users before becoming pregnant switch to e-cigarettes to reduce their exposure. This switch may have benefits, but it does not subvert the independent harm of nicotine that is further compounded by the increasing concentrations found in certain devices.
Much anecdotal evidence exists suggesting e-cigarettes have associations with the development of chronic respiratory symptoms.  Some components of the nicotine aerosol already have known pulmonary toxicity, as previously mentioned. One study evaluated the association of adolescent e-cigarette use and symptoms of chronic bronchitis. Adolescents who currently consumed e-cigarette aerosols had a two-fold increase (odds ratio, 2.02; 95% confidence interval, 1.42-2.88) in bronchitic symptoms (cough, wheezing, etc.) when compared to never users. This effect persisted after adjusting for confounders such as concurrent and past cigarette usage among the participants (odds ratio, 1.70; 95% confidence interval, 1.11-2.59). Overall, more research is needed, but to date, there is evidence to support the negative health consequences for e-cigarette use in novel users and particularly adolescent consumers.
E-cigarettes are frequently cited as smoking cessation and reduction aids by vendors. However, little solid evidence has been published to date to support such a claim. However, one study out of the UK and published in the New England Journal of Medicine randomized 886 participants into two separate treatment groups. One group used standard nicotine replacement products (i.e., patches and pills) and the other used an e-cigarette starter pack. Both groups received behavioral support and counseling. The primary outcome evaluated was the abstinence rate after one year. E-cigarettes showed a statistically significant increase in abstinence rates (8.1%) when compared to the nicotine replacement group. The study utilized a population of smokers pre-motivated to quit and also provided them with ample resources and behavioral support, making the study less generalizable to the public. However, results of this one study suggest in the appropriate environment, and with the proper support, patients who are heavy smokers may benefit from switching to electronic nicotine systems to reduce the adverse symptoms of exposure to cigarette smoke.
Since there is unclear clinical guidance, clinicians may struggle to advise patients on if and how to weave e-cigarettes into their treatment plans. Most experts take the harm reduction approach. FDA approved aids are suggested first due to their established efficacy and safety. E-cigarettes can be utilized second if other aids have failed or patients are insistent. Patients should use flavorless liquids to minimize additives and their unknown effects. Patients should also avoid secondhand vaping indoors and around children because the effects of second and third-hand exposures to these products are also unclear. Lastly, it’s important to emphasize the lack of evidence of the long-term use of these devices and to provide emotional and behavioral support during the process.
Overall rates of cigarette usage were declining among high-school students before e-cigarettes entered the market in 2007.  Anti-tobacco campaigns appeared to be highly effective in addition to public health restrictions on the packaging, advertisement, taxation, and promotion of tobacco products. For example, since 2009, the FDA has prohibited the advertising of tobacco products on television and radio platforms. Many states and local communities have banned cigarette use in public areas such as restaurants and bars. Attitudes towards smoking among adolescents have also shifted in the past couple of decades, and public health campaigns have succeeded in labeling cigarette use as unglamorous and unappealing. Unfortunately, attitudes towards e-cigarettes are not the same. Approximately 20% of high school youth now use some form of e-cigarette device and far less view these products as dangerous when compared to traditional cigarettes. Nearly all e-cigarette companies are owned in part by other major tobacco companies. In the modern era, these companies have been able to subvert previous restrictions by using new-found advertising methods, including social media and youth influencers. Tobacco companies view the youth demographic as a means to increase their lifetime customer base. They go out of their way to reach consumers in developing nations hoping to tighten and expand their grip on an already deeply addicted market. To respond to this crisis, public health organizations have been pushing to regulate the e-cigarette class of products the same as traditional tobacco products; this would hopefully subvert the efforts of tobacco companies to use modern media to reach easily influenced young consumers.
One study attempted to quantify the receptivity of never-smoking American adolescents to tobacco advertising. 41% of the 12- to 13-year-old participants were found to be receptive to at least one of the tobacco advertisements, and the highest response was for the media that included electronic cigarettes. This evidence is concerning because the tobacco industry has historically relied on slowly building general interest among young consumers to cash in later when they come of age and develop full autonomy over their purchases. We know from historical industry documents that tobacco companies target young adults at major transition points in life including moving away from home, entering college, beginning new jobs, joining the military, and hanging out at bars. At the same time as these major life changes, exposure to anti-tobacco public health efforts begin tapering off in this demographic. This reduces the resiliency of never or light smokers from progressing to heavier patterns of use. All of this further supports the idea that stricter regulatory measures towards e-cigarettes are required to protect susceptible adolescents and young adults from carefully crafted and targeted commercial advertising. Early evidence suggests the e-cigarette use in adolescents may lead to heavier cigarette smoking into adulthood.
Multidisciplinary cooperation and education can positively benefit patients and improve outcomes. The more members of the healthcare team asking about e-cigarette use and educating patients, the better. Most interventions will occur in the primary care setting where physicians, nurse practitioners, and pharmacists will discuss smoking cessation with patients. Each team member needs to be educated regarding the risks and benefits of electronic nicotine delivery devices. When questioning patients about their social history, it will be necessary for all team members to ask specifically about e-cigarette use as patients may not consider e-cigarettes to be harmful or in the same category as traditional cigarette smoking and thus may not disclose their use. Due to the rising popularity of these devices in the pediatric population, it is crucial to ask and educate about e-cigarettes during well-child exams. Some adolescences who would not have smoked may try e-cigarettes, which correlate with higher levels of smoking later in life. Interventions with adolescents aimed at smoking have demonstrated effectiveness in decreasing rates of e-cigarette users who later convert to traditional smoking. [Level 1] Currently, traditional cigarette use has far more proven negative health consequences than e-cigarettes, but this is in part because of a lack of research. E-cigarettes are not benign. The adverse effects of nicotine found in e-cigarettes on the cardiovascular system and childhood neurologic development require emphasis. Finally, clinicians should recommend that the public quit smoking. There are no health benefits of smoking and individuals who would like to try vaping, should instead be offered methods of quitting smoking, altogether; not only does smoking discontinuation improve health, it saves money both for the individual and the healthcare system.
Only through a concerted effort by clinicians at all levels can the morbidity associated with smoking decrease. Patients require ongoing education that smoking is harmful to health, and a coordinated effort from all members of the interprofessional team can contribute to that goal. [Level V]
Nurses will have an essential role in collecting and updating the social histories of patients and relaying any e-cigarette use to the healthcare team. The healthcare team needs to be aware of the risks and potential benefits of e-cigarettes and how they relate to patient care and health.
Patients who use e-cigarettes heavily may need nicotine patches/replacement while in the hospital and may experience typical symptoms of nicotine withdrawal for which nurses must monitor.
|||Dinakar Ch,O’Connor GT, The Health Effects of Electronic Cigarettes. The New England journal of medicine. 2016 Dec 29; [PubMed PMID: 28029910]|
|||Hajek P,Phillips-Waller A,Przulj D,Pesola F,Myers Smith K,Bisal N,Li J,Parrott S,Sasieni P,Dawkins L,Ross L,Goniewicz M,Wu Q,McRobbie HJ, A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. The New England journal of medicine. 2019 Feb 14; [PubMed PMID: 30699054]|
|||Soneji S,Barrington-Trimis JL,Wills TA,Leventhal AM,Unger JB,Gibson LA,Yang J,Primack BA,Andrews JA,Miech RA,Spindle TR,Dick DM,Eissenberg T,Hornik RC,Dang R,Sargent JD, Association Between Initial Use of e-Cigarettes and Subsequent Cigarette Smoking Among Adolescents and Young Adults: A Systematic Review and Meta-analysis. JAMA pediatrics. 2017 Aug 1; [PubMed PMID: 28654986]|
|||McConnell R,Barrington-Trimis JL,Wang K,Urman R,Hong H,Unger J,Samet J,Leventhal A,Berhane K, Electronic Cigarette Use and Respiratory Symptoms in Adolescents. American journal of respiratory and critical care medicine. 2017 Apr 15; [PubMed PMID: 27806211]|
|||Qasim H,Karim ZA,Rivera JO,Khasawneh FT,Alshbool FZ, Impact of Electronic Cigarettes on the Cardiovascular System. Journal of the American Heart Association. 2017 Aug 30; [PubMed PMID: 28855171]|
|||Jenssen BP,Boykan R, Electronic Cigarettes and Youth in the United States: A Call to Action (at the Local, National and Global Levels). Children (Basel, Switzerland). 2019 Feb 20; [PubMed PMID: 30791645]|
|||Barrington-Trimis JL,Leventhal AM, Adolescents' Use of [PubMed PMID: 30134127]|
|||Prochaska JJ, The public health consequences of e-cigarettes: a review by the National Academies of Sciences. A call for more research, a need for regulatory action. Addiction (Abingdon, England). 2019 Apr; [PubMed PMID: 30347473]|
|||Goldenson NI,Kirkpatrick MG,Barrington-Trimis JL,Pang RD,McBeth JF,Pentz MA,Samet JM,Leventhal AM, Effects of sweet flavorings and nicotine on the appeal and sensory properties of e-cigarettes among young adult vapers: Application of a novel methodology. Drug and alcohol dependence. 2016 Nov 1; [PubMed PMID: 27676583]|
|||England LJ,Bunnell RE,Pechacek TF,Tong VT,McAfee TA, Nicotine and the Developing Human: A Neglected Element in the Electronic Cigarette Debate. American journal of preventive medicine. 2015 Aug; [PubMed PMID: 25794473]|
|||Rigotti NA, Balancing the Benefits and Harms of E-Cigarettes: A National Academies of Science, Engineering, and Medicine Report. Annals of internal medicine. 2018 May 1; [PubMed PMID: 29435573]|
|||Pierce JP,Sargent JD,White MM,Borek N,Portnoy DB,Green VR,Kaufman AR,Stanton CA,Bansal-Travers M,Strong DR,Pearson JL,Coleman BN,Leas E,Noble ML,Trinidad DR,Moran MB,Carusi C,Hyland A,Messer K, Receptivity to Tobacco Advertising and Susceptibility to Tobacco Products. Pediatrics. 2017 Jun; [PubMed PMID: 28562266]|
|||Ling PM,Glantz SA, Why and how the tobacco industry sells cigarettes to young adults: evidence from industry documents. American journal of public health. 2002 Jun; [PubMed PMID: 12036776]|
|||Leventhal AM,Stone MD,Andrabi N,Barrington-Trimis J,Strong DR,Sussman S,Audrain-McGovern J, Association of e-Cigarette Vaping and Progression to Heavier Patterns of Cigarette Smoking. JAMA. 2016 Nov 8; [PubMed PMID: 27825000]|
|||Conner M,Grogan S,Simms-Ellis R,Flett K,Sykes-Muskett B,Cowap L,Lawton R,Armitage C,Meads D,Schmitt L,Torgerson C,West R,Siddiqi K, Evidence that an intervention weakens the relationship between adolescent electronic cigarette use and tobacco smoking: a 24-month prospective study. Tobacco control. 2019 Jun 28 [PubMed PMID: 31253718]|
|||Layden JE,Ghinai I,Pray I,Kimball A,Layer M,Tenforde M,Navon L,Hoots B,Salvatore PP,Elderbrook M,Haupt T,Kanne J,Patel MT,Saathoff-Huber L,King BA,Schier JG,Mikosz CA,Meiman J, Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Preliminary Report. The New England journal of medicine. 2019 Sep 6; [PubMed PMID: 31491072]|